In patients treated with the combination of venetoclax and obinutuzumab as initial therapy in the CLL-14 study, the IGHV mutational status maintained its importance in both the standard chemoimmunotherapy arm and the BCL2-inhibitor arm with shorter PFS for patients with U-CLL (27). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.